Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cardinal Health ( (CAH) ) has provided an update.
On October 7, 2025, Cardinal Health entered into a new 364-Day Credit Agreement with Bank of America, allowing access to $1 billion of revolving credit until October 6, 2026. This agreement supports general corporate purposes and backs the company’s commercial paper program, with conditions including a financial covenant requiring a Consolidated Net Leverage Ratio of no greater than 3.75 to 1.00.
The most recent analyst rating on (CAH) stock is a Buy with a $190.00 price target. To see the full list of analyst forecasts on Cardinal Health stock, see the CAH Stock Forecast page.
Spark’s Take on CAH Stock
According to Spark, TipRanks’ AI Analyst, CAH is a Neutral.
Cardinal Health’s overall stock score is driven by strong earnings growth and strategic acquisitions, which are expected to enhance future performance. However, significant financial leverage and cash flow management issues present risks. The technical indicators suggest a mild bullish trend, while the valuation appears relatively high, limiting upside potential.
To see Spark’s full report on CAH stock, click here.
More about Cardinal Health
Cardinal Health, Inc. operates in the healthcare industry, providing pharmaceuticals and medical products to hospitals, pharmacies, and other healthcare providers. The company focuses on improving the cost-effectiveness of healthcare delivery.
Average Trading Volume: 2,328,688
Technical Sentiment Signal: Buy
Current Market Cap: $37.67B
See more insights into CAH stock on TipRanks’ Stock Analysis page.